Cellbricks Therapeutics

Celebrating a Landmark Year at Cellbricks Therapeutics!   2024 has been an amazing year for us at Cellbricks Therapeutics. We've achieved incredible levels of innovation and impact, making it a year to remember. Our team has worked hard to make progress towards our goal of bringing life-saving tissue therapeutics to patients in need. Let's take a look at what we've achieved together this year:   ➜ Scientific breakthroughs: Secured positive in vivo results for our therapeutic program, as we progress to the clinic, demonstrating the potential of our tissue therapeutics and biofabrication platform.   ➜ Global team expansion: Assembled our chemistry, biology, tissue engineering and engineering teams from diverse backgrounds and nationalities, incl. Mexico, Finland, the US, Ukraine, France, Ireland, Portugal, the UK, Iran, India, Bulgaria, and Germany.   ➜ Financial growth: Secured EUR 5m in venture capital and research funding, broadening our investor base with partners ACT Venture Partners, VU Venture Partners, and numerous supportive business angels.   ➜ Tech advancements: Delivered the first of our new clinical grade proprietary light-based 3D-Bioprinter, enabling closer collaboration with our partners such as Charité, Berlin.   ➜ Advisory excellence: Expanded our Advisory Board with experts such as Troy Dale, Kattayoun (Kathy) Kordy, M.D., Rajiv Jalan, Korkut Uygun, and Milad Milo Rezvani, providing strategic and scientific insights to guide our forward momentum.   ➜ Strategic growth: Relocated to a larger facility on the Bayer campus in Berlin, boosting our operational capabilities. Our Lab Warming Party was a blast - thanks to all who joined!   ➜ US expansion: Marked a major milestone with the opening our US office at The Engine Accelerator, Cambridge, MA, solidifying our presence as a transatlantic innovator in healthcare. Not forgetting the Berlin delegation led Kai Wegner (Mayor of Berlin) and Franziska Giffey (Deputy mayor) stopped by.   ➜ Rebranding: Rebranded to Cellbricks Therapeutics, following our evolution from a 3D-bioprinting startup to a cutting-edge therapeutics company.   ➜ Media & public engagement: Spread our mission to revolutionize healthcare across multiple channels. Spread our mission to revolutionize healthcare through multiple channels. Our team has engaged in pitches, presentations, conferences, poster sessions, panel discussions, award ceremonies, and TV and newspapers features, effectively extending our impact and visibility.   Of course, none of this would have been possible without the dedication of our incredible team, the support of our partners and investors, and the guidance of our advisors and the help of our families. Thank you for being part of this journey. Looking ahead to 2025, we’re excited about what we’ll accomplish together next!   Here's to another year of passion, innovation, and community! 🚀   The Cellbricks Team #CellbricksTherapeutics #TissueTherapeutics #MissionDriven #Teamwork #2024Recap

As we close out the year, we would like to share an important update regarding our leadership team: Joachim von Arnim, our co-Managing Director and Chief Strategy Officer as well as a friend and business partner, has made the decision to step back from his operational role. Moving forward, Alexander Leutner will continue to lead Cellbricks Therapeutics alongside Dr. Simon MacKenzie together with our co-founders Alexander Thomas, Dr. Tobias Lam, and Program Lead Dr. Alicia Ruppelt, advancing Cellbricks’ mission: bringing life-saving tissue therapeutics to patients in need. Joachim has been central to the development of Cellbricks. Four years ago, Joachim, one of Cellbricks’ first two investors, and Alexander became co-Managing Directors. Together, they have successfully transformed the business. Cellbricks evolved from a German bioprinting startup to a transatlantic tissue therapeutics company, called Cellbricks Therapeutics. Since the foundation of the business’s future success has now been created, Joachim has decided to leave his role and pursue new endeavors.   Upon learning of Joachim’s decision, Alexander shared his appreciation: “On behalf of the board and the entire Cellbricks team, I would like to express our heartfelt gratitude to you, Joachim, for your invaluable contributions and for laying the groundwork for our future endeavors. Building this company with you has been a profound journey. You are more than a business partner; you are a friend I have known since our university days. I wish you all the best for the next chapter.”

The event "Pioneers - Germany's 30 until 2030" - an initiative by WirtschaftsWoche, hosted as part of Handelsblatt's Winter Camp - celebrated 30 visionary individuals & teams who are driving breakthroughs in science, business, and society until 2030. This week, our CEO Alexander Leutner proudly represented the Cellbricks Therapeutics team at the event. Being recognized as a disruptor underlines our steadfast commitment to bringing life-saving tissue therapeutics to the clinic. We’re also inspired by the other transformative ideas, teams and individuals recognized by Germany's renowned press. Follow us changemakers closely - we are shaping the future! Heike Freund (Marvel Fusion) | Susanne Wiegand (RENK Group) | Dr. Michael Förtsch (Q.ANT) | Matthias Wiedenfels (BioCopy AG) | Katharina Poehlmann (A.P. Moller - Maersk) | Brigitte Knopf (Zukunft KlimaSozial) | David Reger (NEURA Robotics) | Lilian Schwich (cylib) | Dr. Claudia Ulbrich (Cardior Pharmaceuticals) | Dr. Maximilian Oehl (Media Force) | Philipp Strack (Yale University) | Jan Goetz (IQM Quantum Computers) |  🟣 Elias Schneider (Codesphere) | Simon Jäger (Massachusetts Institute of Technology) | Max Viesmann (Viessmann) | Nicole Büttner (Merantix Momentum) A big shoutout to the teams at Wirtschaftswoche and Handelsblatt and the support by SAP for launching this initiative and for proving that Germany is still a powerhouse for groundbreaking innovation. This is a strong reminder that the German economy has lots of potential to stand out and doesn’t need to shy away in the global race to claim a leading position.

Let’s creat the future we envision! I’m thankful to Horst von Buttlar and the WirtschaftsWoche team for recognizing me as one of 30 individuals shaping Germany’s future until 2030. It reflects the amazing dedication of our team at Cellbricks Therapeutics pushing forward our vision of life-saving tissue therapeutics. A heartfelt thank you to you, our founders, investors, and everyone who is part of this journey! This isn’t about personal recognition, it’s a call to action: 1. Revitalize Germany’s innovation power: In challenging times for industries like automotive, there’s immense potential to position Germany and Europe at the forefront of deep-tech and life sciences. Let’s use transformation and create new opportunities! 2. Spread the start-up mindset: Every young person should feel empowered to choose between a traditional career or boldly starting their own venture. Start-ups solve real problems and reshape the world - let’s inspire the next generation to believe anything is possible. 3. Amplify & empower role models: There are countless innovators - some seasoned, others just starting - who deserve the spotlight. Let’s support and strengthen the people and ideas driving our deep-tech ecosystem forward and foster a “can do” attitude that inspires action and progress. This initiative should inspire to keep pushing boundaries in technology, healthcare, business, and beyond. "Progress comes from action", whether founding a venture, tackling the next big challenge, or (as I’ve personally experienced) donating a kidney to someone in need. We all have the power to make a difference and build a brighter future for Germany and Europe. Here’s to the incredible people & organizations inspiring and supporting the deep-tech start-up ecosystem in Germany and beyond: Dr. Claudia Ulbrich, Dr. Matthias Wiedenfels, Lilian Schwich, Daniel Metzler, Nils Aldag, Max Viessmann, Nicole Büttner, Jan Goetz, David Reger, Thorsten Chmielus, Heike Freund, Dr. Michael Förtsch, Springboard Health Angels, Bayer Co.Lab, Dr. Philipp Herzig, Andreas Schmidt (PhD.), Jan Leike, Falling Walls Foundation, Peer M. Schatz, Dr.-Ing. Herbert Mangesius, Vsquared Ventures, Verena Pausder, Startup-Verband, Rafael Laguna de la Vera, SPRIND - Bundesagentur für Sprunginnovationen, Lenard F. Krawinkel etc. #Germanys30until2030 #30bis2030 #Innovation #Entrepreneurship #Biotech #DeepTech #RoleModels #TissueTherapeutics

Are you a start-up working in the cell and gene therapy or oncology field and looking for the perfect environment to accelerate your growth? We highly recommend applying to the newly renovated Bayer Co.Lab located at Bayer | Pharmaceuticals' global HQ campus, Berlin. As proud Co.Lab alumni, Cellbricks Therapeutics looks back at this incredible opportunity with great appreciation - it was a fantastic springboard that helped us get to where we are today. At Co.Lab, you gain direct access to expertise in R&D, manufacturing, regulatory, and medical fields - not to mention the valuable connections with other innovative start-ups! Here are impressions from the last week opening with Stefan Oelrich (President Pharmaceuticals at Bayer AG) and Kai Wegner (Mayor of Berlin) and many more. And on a fun note, we're thrilled they decided to make our company colors their own! 😉 #BayerCoLab #Innovation #startups #ATMP #CellAndGene #CellbricksTherapeutics

This week, we had the pleasure of hosting Verena Pausder, Chairwoman of the German Startup Association (Startup-Verband) acompanied by Sarah Heuberger from manager magazin and Friederike Rohmann with her film crew from ARD at Cellbricks!   As a passionate ambassador for Germany’s deeptech ecosystem, Verena makes time to connect with leading deeptech startups in the country, whenever her schedule allows. We were honored that Cellbricks - pioneering a therapeutic revolution with 3D-bioprinted tissue therapies to address severe diseases - was included in her journey.   Our CEO, Alexander Leutner, shared insights into our progress and discussed challenges like talent and regulation, as well as the immense potential of biotech to transform millions of patient lives. It’s fantastic to see biotech gaining recognition alongside space and quantum technologies as a key driver of impact and innovation.   Thank you, Verena, for shining a spotlight on deeptech and for the inspiring exchange. We’re happy to be part of this exciting movement for Germany’s tech future! 🚀    #DeepTech #Biotech #Innovation #StartupEcosystem #CellbricksTherapeutics #TissueTherapeutics

This week, we proudly celebrated the launch of our US subsidiary Cellbricks Therapeutics Inc. in Cambridge, MA.  It is an honor to have the Governing Mayor of Berlin, Kai Wegner, cut the ribbon together with the Deputy Mayor and Senator for Economics, Franziska Giffey, and the State Secretary for Research, Dr. Henry Marx. We are proud to have been selected as a member of The Engine Accelerator, MIT's accelerator known as The Home for Tough Tech. We thank Emily Knight (CEO & President of The Engine) and her team for the warm welcome. Cellbricks Therapeutics is now transforming into a truly transatlantic company. The goal is to synergistically leverage the strengths of both ecosystems, Berlin and Boston, to provide patients with access to life-saving tissue therapeutics as quickly as possible. To emphasize our focus on making cell therapy implantable and thus delivering life-saving tissue therapeutics, we are expanding our brand name and all Cellbricks will be known as Cellbricks Therapeutics. Finally, we'd like to thank Dane C. and Johannes Fruehauf for making this incredible moment possible with their unwavering support! #CellbricksTherapeutics #USLaunch #CambridgeMA 

This week, we proudly celebrated the launch of our US subsidiary Cellbricks Therapeutics Inc. in Cambridge, MA.  It is an honor to have the Governing Mayor of Berlin, Kai Wegner, cut the ribbon together with the Deputy Mayor and Senator for Economics, Franziska Giffey, and the State Secretary for Research, Dr. Henry Marx. We are proud to have been selected as a member of The Engine Accelerator, MIT's accelerator known as The Home for Tough Tech. We thank Emily Knight (CEO & President of The Engine) and her team for the warm welcome. Cellbricks Therapeutics is now transforming into a truly transatlantic company. The goal is to synergistically leverage the strengths of both ecosystems, Berlin and Boston, to provide patients with access to life-saving tissue therapeutics as quickly as possible. To emphasize our focus on making cell therapy implantable and thus delivering life-saving tissue therapeutics, we are expanding our brand name and all Cellbricks will be known as Cellbricks Therapeutics. Finally, we'd like to thank Dane C. and Johannes Fruehauf for making this incredible moment possible with their unwavering support! #CellbricksTherapeutics #USLaunch #CambridgeMA 

Our leadership team is excited to kick off our trip to Cambridge, MA! Next week, we’ll be in Boston connecting with partners, peers, and investors, and exploring new opportunities. If you'd like to meet with us and catch up on our latest progress, feel free to reach out directly. And be sure to stay tuned - we’ll be sharing some exciting updates in the coming days! Alexander Leutner | Simon MacKenzie | Joachim von Arnim | Alexander Thomas | Alicia Ruppelt | Tobias Lam #Cellbricks #TissueTherapeutics #RegenerativeMedicine #Boston #CambridgeMA

Meet us at #BIOEurope 2024 and talk with us about our live-saving tissue therapeutics and how we are making cell therapies implantable. Our COO, Simon MacKenzie, will be on-site for one-to-one partnering meetings and to catch up on latest industry trends, network with peers, and share insights on our tissue therapeutics programs. You can also meet with us at the 🇩🇪 German Pavilion.   ➡️ Reach out to Simon directly (here or through the partnering platform) to set up a meeting and explore potential collaborations or partnership opportunities.    #TissueTherapeutics #MakingCellTherapyImplantable #Biofabrication #Cellbricks #BioEurope #GermanPavillion